Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $222.86 USD
Change Today -0.16 / -0.07%
Volume 1.6M
VRX On Other Exchanges
Symbol
Exchange
Toronto
New York
Mexico
Frankfurt
As of 8:04 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by VALEANT PHARMACEUTICALS INTE (VRX) in the last 6 months

Announced 03/9/15
3.30B for Valeant Pharmaceuticals International, Inc.
Merger/Acquisition

Pershing Square Capital Management, L.P. through its fund Pershing Square Holdings, Ltd. (ENXTAM:PSH) acquired 4.9% stake in Valeant Pharmaceuticals International, Inc. (TSX:VRX) for $3.3 billion on March 9, 2015. Pershing acquired 16.5 million shares of Valeant. Tim Burt of StockWell Communications acted as public relations advisor in the deal. Davies Ward Phillips & Vineberg LLP acted as the legal advisor to Pershing Square Holdings, Ltd.


VRX's price was unchanged after the transaction was announced on 03/9/15.
 
Announced 01/29/15
495.00M for Dendreon Corp, Substantially All Assets
Merger/Acquisition

Valeant Pharmaceuticals International, Inc (TSX: VRX) entered into a stalking horse asset purchase agreement to acquire Provenge product and certain other assets of Dendreon Corp (OTCPK:DNDN.Q) for approximately $300 million in cash on January 29, 2015. Valeant Pharmaceuticals will deposit 10% of consideration into escrow which would be released at closing. Under the terms of the agreement, Valeant Pharmaceuticals International, Inc will acquire the world-wide rights ...
Read More


VRX's price was unchanged after the transaction was announced on 01/29/15.
Investor / Buyer
Valeant Pharmaceuticals International, Inc.
Creditor / Lender
Dendreon Corp.
 
Announced 11/20/14
Valeant Pharmaceuticals International, Inc.
Buyback

Valeant Pharmaceuticals International, Inc. (TSX:VRX) announces a share repurchase program. Under the program, the company will repurchase up to $2,000 million worth of its common shares, senior notes and/or other debt or shares that may be issued prior to the completion of the program. The repurchases of common shares will be made at prevailing market prices of such shares on the NYSE or the TSX, as the case may be, at the time of the acquisition and will be made in ...
Read More


VRX's price was unchanged after the transaction was announced on 11/20/14.
 
Announced 11/17/14
20.00M for NicOx Inc.
Merger/Acquisition

Valeant Pharmaceuticals International, Inc. (TSX:VRX) acquired Nicox Inc. from Nicox SA (ENXTPA:COX) for $20 million in cash on November 17, 2014. Valeant has acquired Nicox Inc. for $10 million in cash, plus further cash payments of up to $10 million based upon Valeant achieving certain sales targets with the transferred products. Valeant has acquired most of the Nicox commercial infrastructure in the US associated with diagnostics, while Nicox has retained a number ...
Read More


VRX's price was unchanged after the transaction was announced on 11/17/14.
Investor / Buyer
Valeant Pharmaceuticals International, Inc.
Creditor / Lender
Nicox SA
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $222.86 USD -0.16

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $289.81 USD +0.07
Astellas Pharma Inc ¥1,875 JPY +5.50
Bristol-Myers Squibb Co $65.32 USD +0.66
Mylan NV $73.05 USD -0.84
Sun Pharmaceutical Industries Ltd 958.45 INR +10.70
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 75.9x
Price/Sales 8.8x
Price/Book 11.8x
Price/Cash Flow 30.6x
TEV/Sales 5.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.